Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

ACE2 levels are altered in comorbidities linked to severe outcome in COVID-19 Subtitle: ACE2 serum levels are increased in metabolic disease

Emilsson, Valur and Gudmundsson, Elias F and Aspelund, Thor and Jonsson G, Brynjolfur and Gudjonsson, Alexander and Laurner, Lenore J and Lamb, John and Gudmundsdottir, Valborg and Jennings, Lori and Gudnason, Vilmundur (2020) ACE2 levels are altered in comorbidities linked to severe outcome in COVID-19 Subtitle: ACE2 serum levels are increased in metabolic disease. https://medrxiv.org/cgi/content/short/2020.06.04.20122044v1.

Abstract

Importance Recent reports have shown that hypertension, kidney disease, obesity, type 2 diabetes (T2D) and cardiovascular disease are the among the most common comorbidities associated with severe outcome from the current coronavirus disease 2019 (COVID-19), which may be related to the frailty and/or medication use of this patient population. However, it´s possible that individuals with these comorbidities have altered serum levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2.
Objective To examine if individuals that manifest with comorbidities associated with severe outcome from COVID-19 have altered circulating levels of ACE2.
Design, Setting, and Participants A single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavik Study (AGES-RS) of the elderly (mean age 75±6 years) investigated with respect to hypertension, T2D, obesity or CHD.
Main Outcomes and Measures Associations of serum levels of ACE2 were examined in the AGES-RS study population according to body mass index (BMI) (kg/m2), hypertension, type 2 diabetes (T2D), CHD and other relevant phenotypes.
Results ACE2 levels were significantly elevated in the sera from smokers and individuals suffering from T2D and/or obesity, while males had reduced ACE2 levels
Conclusions and Relevance ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as a circulating biomarker for severity of outcome in COVID-19.

Item Type: Article
Keywords: SARS-CoV2, COVID-19, ACE2
Date Deposited: 07 Jul 2020 00:45
Last Modified: 07 Jul 2020 00:45
URI: https://oak.novartis.com/id/eprint/42801

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.